バイオリアクター市場：2035年までの業界動向と世界の予測- 製造材料別、バイオプロセス別、生物学的製剤別、主要地域別

バイオリアクターの市場規模は、2024年に167億米ドルになるとみられ、2024年～2035年の予測期間中に11.1％のCAGRで拡大すると予測されています。

バイオリアクターは、正確に制御された条件下で細胞や組織の成長を促進するために、上流のバイオ製造に使用される特殊な容器を表しています。これらの条件には、温度、pH、圧力、通気、栄養レベルなどの要素が含まれ、生きた細胞や細胞成分の環境を最適化することを目的としています。第一の目標は、基質から多様な生物学的産物への変換を促進することです。これらの製品は、ワクチン、融合タンパク質、抗体、ホルモン、インターロイキン、酵素などの治療用タンパク質から、細胞ベースやオリゴヌクレオチドベースの治療薬、遺伝子治療用のレトロウイルスベクター、創薬研究に不可欠な2Dや3Dの組織コンストラクトを模倣した高度なin vitroモデルなどの最先端の医薬品まで多岐にわたる。一般的に、これらのバイオリアクターは円筒形でステンレス鋼製であることが多く、大きさはミリリットルから数リットルまで様々で、様々なバイオプロセスのニーズや操作モードに合わせて調整されています。

バイオ医薬品に対する世界の需要の急増が、バイオプロセス用品市場の成長を大きく後押ししています。企業が自社でバイオ医薬品製造施設を設立するか、専門機関に製造を委託するようになったため、臨床用および商業用スケールのバイオリアクターの需要が急増しています。現在の推定では、自社生産と外部委託の両方を含めると、世界のバイオリアクターの生産能力は1,300万リットルを超えています。このような膨大な需要を背景に、バイオリアクター市場は競争の場へと発展しており、多様な用途に合わせた広範なバイオリアクターの設計、エンジニアリング、製造の専門知識を誇る活発な企業が数多く存在します。従来のステンレス製バイオリアクターから、使い捨て/単回使用バイオリアクター、攪拌槽型バイオリアクター、小規模バイオリアクター、エアリフト・バイオリアクター、灌流バイオリアクター、バブルカラム・バイオリアクター、光バイオリアクターまで、幅広い製品が提供されています。

当レポートでは、世界のバイオリアクター市場について調査し、市場の概要とともに、製造材料別、バイオプロセス別、生物学的製剤別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 バイオリアクターメーカー：市場情勢

第5章 企業競争力分析

• 章の概要
• 前提/ 主要パラメータ
• 調査手法
• 企業競争力分析：中小企業
• 企業競争力分析：中規模企業
• 企業競争力分析：大規模企業と超大規模企業

第6章 企業プロファイル

• 章の概要
• Applikon Biotechnology
• Bionet
• Cytiva
• Eppendorf
• Merck
• Ollital Technology
• Parr Instrument Company
• Sartorius
• Shanghai Bailun Biological Technology
• Solaris Biotech（acquired by Donaldson Company）
• Solida Biotech
• Zhengzhou Laboao Instrument Equipment（LABAO）

第7章 能力分析

第8章 ケーススタディ：バイオプロセスコントローラと自動化システム

第9章 市場予測

• 章の概要
• 主な前提と予測調査手法
• 世界のバイオリアクター市場、2023年～2035年：製造材料別
• 世界のガラスバイオリアクター市場、2023年～2035年
• 世界のステンレス鋼バイオリアクター市場、2023年～2035年
• 世界の使い捨てバイオリアクター市場、2023年～2035年
• 世界のバイオリアクター市場、2023年～2035年：バイオプロセス別

第10章 エグゼクティブ洞察

第11章 結論

第12章 付録1：表形式のデータ

第13章 付録2：企業・団体一覧

List of Tables

• Table 4.1 Bioreactor Manufacturers: List of Companies
• Table 4.2 Bioreactor Manufacturers: Information on Geographical Reach
• Table 4.3 Bioreactor Manufacturers: Information on Volume and Type of Bioreactor
• Table 4.4 Bioreactor Manufacturers: Information on Scale of Operation and Scalability
• Table 4.5 Bioreactor Manufacturers: Type of Bioprocess and Type of Cell Culture
• Table 4.6 Bioreactor Manufacturers: Information on Mode of Operation and Type of End-user
• Table 6.1 Bioreactor Manufacturers: List of Profiled Companies
• Table 6.2 Applikon Biotechnology: Company Snapshot
• Table 6.3 Applikon Biotechnology: Bioreactor Portfolio
• Table 6.4 Applikon Biotechnology: Recent Developments and Future Outlook
• Table 6.5 Bionet: Company Snapshot
• Table 6.6 Bionet: Bioreactor Portfolio
• Table 6.7 Bionet: Recent Developments and Future Outlook
• Table 6.8 Cytiva: Company Snapshot
• Table 6.9 Cytiva: Bioreactor Portfolio
• Table 6.10 Cytiva: Recent Developments and Future Outlook
• Table 6.11 Eppendorf: Company Snapshot
• Table 6.12 Eppendorf: Bioreactor Portfolio
• Table 6.13 Eppendorf: Recent Developments and Future Outlook
• Table 6.14 Merck: Company Snapshot
• Table 6.15 Merck: Bioreactor Portfolio
• Table 6.16 Merck: Recent Developments and Future Outlook
• Table 6.17 Ollital Technology: Company Snapshot
• Table 6.18 Ollital Technology: Bioreactor Portfolio
• Table 6.19 Ollital Technology: Recent Developments and Future Outlook
• Table 6.20 Parr Instrument Company: Company Snapshot
• Table 6.21 Parr Instrument Company: Bioreactor Portfolio
• Table 6.22 Parr Instrument Company: Recent Developments and Future Outlook
• Table 6.23 Sartorius: Company Snapshot
• Table 6.24 Sartorius: Bioreactor Portfolio
• Table 6.25 Sartorius: Recent Developments and Future Outlook
• Table 6.26 Shanghai Bailun Biological Technology: Company Snapshot
• Table 6.27 Shanghai Bailun Biological Technology: Bioreactor Portfolio
• Table 6.28 Shanghai Bailun Biological Technology: Recent Developments and Future Outlook
• Table 6.29 Solaris Biotech: Company Snapshot
• Table 6.30 Solaris Biotech: Bioreactor Portfolio
• Table 6.31 Solaris Biotech: Recent Developments and Future Outlook
• Table 6.32 Solida Biotech: Company Snapshot
• Table 6.33 Solida Biotech: Bioreactor Portfolio
• Table 6.34 Solida Biotech: Recent Developments and Future Outlook
• Table 6.35 Zhengzhou Laboao Instrument Equipment (LABAO): Company Snapshot
• Table 6.36 Zhengzhou Laboao Instrument Equipment (LABAO): Bioreactor Portfolio
• Table 6.37 Zhengzhou Laboao Instrument Equipment (LABAO): Recent Developments and Future Outlook
• Table 7.1 Capacity Analysis: Information on Contract Biomanufacturing Capacity
• Table 7.2 Capacity Analysis: Average Capacity per Category (Sample Data Set)
• Table 7.3 Capacity Analysis: Average Capacity for Mammalian Expression System (Sample Data Set)
• Table 7.4 Capacity Analysis: Average Capacity for Microbial Expression System (Sample Data Set)
• Table 7.5 Capacity Analysis: Global Distribution of Contract, in-house and Hybrid Biomanufacturing Capacity
• Table 8.1 Bioprocess Control Software: Information on Key Features, Compatibility with Bioreactor System and Process Controlled
• Table 8.2 Upstream Controllers: Information on Key Features, Type of Bioprocess and Compatibility with Bioreactor System
• Table 8.3 Downstream Controller Systems: Information on Key Features, Type of System, Type of Bioprocess and Application Area
• Table 10.1 Ensofa Projects: Key Highlights
• Table 10.2 Sunrise Process Equipments: Key Highlights
• Table 10.3 CerCell: Key Highlights
• Table 10.4 CelVivo: Key Highlights
• Table 12.1 Bioreactor Manufacturers: Distribution by Year of Establishment
• Table 12.2 Bioreactor Manufacturers: Distribution by Company Size
• Table 12.3 Bioreactor Manufacturers: Distribution by Region of Headquarters
• Table 12.4 Bioreactor Manufacturers: Distribution by Location of Headquarters
• Table 12.5 Bioreactor Manufacturers: Distribution by Year of Establishment and Region of Headquarters
• Table 12.6 Bioreactor Manufacturers: Distribution by Company Size and Region of Headquarters
• Table 12.7 Bioreactor Manufacturers: Distribution by Year of Establishment, Company Size and Region of Headquarters
• Table 12.8 Bioreactor Manufacturers: Distribution by Geographical Reach
• Table 12.9 Bioreactor Manufacturers: Distribution by Region of Headquarters Region and Geographical Reach
• Table 12.10 Bioreactor Manufacturers: Distribution by Capacity
• Table 12.11 Bioreactor Manufacturers: Distribution by Scale of Operation
• Table 12.12 Bioreactor Manufacturers: Distribution by Scalability
• Table 12.13 Bioreactor Manufacturers: Distribution by Type of Bioprocess
• Table 12.14 Bioreactor Manufacturers: Analysis by Type of Cell Culture
• Table 12.15 Bioreactor Manufacturers: Analysis by Mode of Operation
• Table 12.16 Bioreactor Manufacturers: Analysis by Type of End-user
• Table 12.17 Cytiva: Annual Revenues, FY 2017-FY 2021 (USD Million)
• Table 12.18 Eppendorf: Annual Revenues, FY 2017-FY 2021 (EUR Million)
• Table 12.19 Merck: Annual Revenues, FY 2017-FY 2022 (EUR Billion)
• Table 12.20 Sartorius: Annual Revenues, FY 2017-FY 2022 (EUR Billion)
• Table 12.21 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Fabrication Material
• Table 12.22 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Source of Cell Culture
• Table 12.23 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Reactor Volume
• Table 12.24 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Type of Manufacturer
• Table 12.25 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Key Geographical Regions
• Table 12.26 Bioprocess Control Software: Distribution by Scale of Operation
• Table 12.27 Bioprocess Control Software: Distribution by Key Features
• Table 12.28 Bioprocess Control Software: Distribution by Compatibility with Systems
• Table 12.29 Bioprocess Control Software: Distribution by Type of Process Controlled
• Table 12.30 Bioprocess Control Software Developers: Distribution by Year of Establishment
• Table 12.31 Bioprocess Control Software Developers: Distribution by Company Size
• Table 12.32 Bioprocess Control Software Developers: Distribution by Location of Headquarters
• Table 12.33 Upstream Controllers: Distribution by Scale of Operation
• Table 12.34 Upstream Controllers: Distribution by Key Features
• Table 12.35 Upstream Controllers: Distribution by Compatibility with Bioreactor Systems
• Table 12.36 Upstream Controllers: Distribution by Type of Bioprocess
• Table 12.37 Upstream Controllers: Distribution by Type of Process Controlled
• Table 12.38 Upstream Controller Developers: Distribution by Year of Establishment
• Table 12.39 Upstream Controller Developers: Distribution by Company Size
• Table 12.40 Upstream Controller Developers: Distribution by Location of Headquarters
• Table 12.41 Downstream Controller Systems: Distribution by Scale of Operation
• Table 12.42 Downstream Controller Systems: Distribution by Key Features
• Table 12.43 Downstream Controller Systems: Distribution by Type of System
• Table 12.44 Downstream Controller Systems: Distribution by Type of Bioprocess
• Table 12.45 Downstream Controller Systems: Distribution by Application Area
• Table 12.46 Downstream Controller System Developers: Distribution by Year of Establishment
• Table 12.47 Downstream Controller System Developers: Distribution by Company Size
• Table 12.48 Downstream Controller System Developers: Distribution by Location of Headquarters
• Table 12.49 Global Bioreactors Market, 2023-2035 (USD Billion)
• Table 12.50 Global Bioreactors Market, 2023-2035: Distribution by Fabrication Material
• Table 12.51 Global Glass Bioreactors Market, 2023-2035
• Table 12.52 Global Stainless Steel Bioreactors Market, 2023-2035
• Table 12.53 Global Single use Bioreactors Market, 2023-2035
• Table 12.54 Global Bioreactors Market, 2023-2035: Distribution by Type of Bioprocess
• Table 12.55 Global Bioreactors Market for Batch and Fed-batch Process, 2023-2035
• Table 12.56 Global Bioreactors Market for Continuous Process, 2023-2035
• Table 12.57 Global Bioreactors Market, 2023-2035: Distribution by Type of Biologic
• Table 12.58 Global Bioreactors Market for Antibodies, 2023-2035
• Table 12.59 Global Bioreactors Market for Vaccines, 2023-2035
• Table 12.60 Global Bioreactors Market for Cell Therapies, 2023-2035
• Table 12.61 Global Bioreactors Market for Other Biologics, 2023-2035
• Table 12.62 Global Bioreactors Market, 2023-2035: Distribution by Key Geographical Regions
• Table 12.63 Bioreactors Market in North America, 2023-2035
• Table 12.64 Bioreactors Market in Europe, 2023-2035
• Table 12.65 Bioreactors Market in Asia-Pacific, 2023-2035
• Table 12.66 Bioreactors Market in Rest of the World, 2023-2035

List of Figures

• Figure 2.1 Executive Summary: Overall Market Landscape
• Figure 2.2 Executive Summary: Capacity Analysis
• Figure 2.3 Executive Summary: Market Forecast
• Figure 3.1 Components of a Bioreactor
• Figure 3.2 Types of Bioreactors (based on Type of Bioprocess)
• Figure 3.3 Types of Bioreactors (based on Mode of Action)
• Figure 3.4 Industries Employing Bioreactors
• Figure 3.5 Applications of Bioreactors in Pharmaceutical Industry
• Figure 4.1 Bioreactor Manufacturers: Distribution by Year of Establishment
• Figure 4.2 Bioreactor Manufacturers: Distribution by Company Size
• Figure 4.3 Bioreactor Manufacturers: Distribution by Region of Headquarters
• Figure 4.4 Bioreactor Manufacturers: Distribution by Location of Headquarters
• Figure 4.5 Bioreactor Manufacturers: Distribution by Year of Establishment and Region of Headquarters
• Figure 4.6 Bioreactor Manufacturers: Distribution by Company Size and Region of Headquarters
• Figure 4.7 Bioreactor Manufacturers: Distribution by Year of Establishment, Company Size and Region of Headquarters
• Figure 4.8 Bioreactor Manufacturers: Distribution by Geographical Reach
• Figure 4.9 Bioreactor Manufacturers: Distribution by Region of Headquarters and Geographical Reach
• Figure 4.10 Bioreactor Manufacturers: Distribution by Capacity
• Figure 4.11 Bioreactor Manufacturers: Distribution by Scale of Operation
• Figure 4.12 Bioreactor Manufacturers: Distribution by Scalability
• Figure 4.13 Bioreactor Manufacturers: Distribution by Type of Bioprocess
• Figure 4.14 Bioreactor Manufacturers: Distribution by Type of Cell Culture
• Figure 4.15 Bioreactor Manufacturers: Distribution by Mode of Operation
• Figure 4.16 Bioreactor Manufacturers: Distribution by Type of End-user
• Figure 5.1 Competitiveness Analysis: Small Companies
• Figure 5.2 Competitiveness Analysis: Small Companies based in North America
• Figure 5.3 Competitiveness Analysis: Small Companies based in Europe
• Figure 5.4 Competitiveness Analysis: Small Companies based in Asia-Pacific and Rest of the World
• Figure 5.5 Competitiveness Analysis: Mid-sized Companies
• Figure 5.6 Competitiveness Analysis: Mid-sized Companies based in North America
• Figure 5.7 Competitiveness Analysis: Mid-sized Companies based in Europe
• Figure 5.8 Competitiveness Analysis: Mid-sized Companies based in Asia-Pacific and Rest of the World
• Figure 5.9 Competitiveness Analysis: Large and Very Large Companies
• Figure 5.10 Competitiveness Analysis of Bioreactor Manufacturers: Competitiveness Score of Top Players
• Figure 6.1 Cytiva: Annual Revenues, FY 2017-FY 2021 (USD Million)
• Figure 6.2 Eppendorf: Annual Revenues, FY 2017-FY 2021 (EUR Million)
• Figure 6.3 Merck: Annual Revenues, FY 2017-FY 2022 (EUR Billion)
• Figure 6.4 Sartorius: Annual Revenues, FY 2017-FY 2022 (EUR Billion)
• Figure 7.1 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Fabrication Material
• Figure 7.2 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Source of Cell Culture
• Figure 7.3 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Reactor Volume
• Figure 7.4 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Type of Manufacturer
• Figure 7.5 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Key Geographical Regions
• Figure 8.1 Bioprocess Control Software: Distribution by Scale of Operation
• Figure 8.2 Bioprocess Control Software: Distribution by Key Features
• Figure 8.3 Bioprocess Control Software: Distribution by Compatibility with System
• Figure 8.4 Bioprocess Control Software: Distribution by Type of Process Controlled
• Figure 8.5 Bioprocess Control Software Developers: Distribution by Year of Establishment
• Figure 8.6 Bioprocess Control Software Developers: Distribution by Company Size
• Figure 8.7 Bioprocess Control Software Developers: Distribution by Location of Headquarters
• Figure 8.8 Upstream Controllers: Distribution by Scale of Operation
• Figure 8.9 Upstream Controllers: Distribution by Key Features
• Figure 8.10 Upstream Controllers: Distribution by Compatibility with Bioreactor System
• Figure 8.11 Upstream Controllers: Distribution by Type of Bioprocess
• Figure 8.12 Upstream Controllers: Distribution by Type of Process Controlled
• Figure 8.13 Upstream Controller Developers: Distribution by Year of Establishment
• Figure 8.14 Upstream Controller Developers: Distribution by Company Size
• Figure 8.15 Upstream Controller Developers: Distribution by Location of Headquarters
• Figure 8.16 Downstream Controller Systems: Distribution by Scale of Operation
• Figure 8.17 Downstream Controller Systems: Distribution by Key Features
• Figure 8.18 Downstream Controller Systems: Distribution by Type of System
• Figure 8.19 Downstream Controller Systems: Distribution by Type of Bioprocess
• Figure 8.20 Downstream Controller Systems: Distribution by Application Area
• Figure 8.21 Downstream Controller System Developers: Distribution by Year of Establishment
• Figure 8.22 Downstream Controller System Developers: Distribution by Company Size
• Figure 8.23 Downstream Controller System Developers: Distribution by Location of Headquarters
• Figure 9.1 Global Bioreactors Market, 2023-2035 (USD Billion)
• Figure 9.2 Global Bioreactors Market, 2023-2035: Distribution by Fabrication Material
• Figure 9.3 Global Glass Bioreactors Market, 2023-2035
• Figure 9.4 Global Stainless Steel Bioreactors Market, 2023-2035
• Figure 9.5 Global Single use Bioreactors Market, 2023-2035
• Figure 9.6 Global Bioreactors Market, 2023-2035: Distribution by Type of Bioprocess
• Figure 9.7 Global Bioreactors Market for Batch and Fed-batch Process, 2023-2035
• Figure 9.8 Global Bioreactors Market for Continuous Process, 2023-2035
• Figure 9.9 Global Bioreactors Market, 2023-2035: Distribution by Type of Biologic
• Figure 9.10 Global Bioreactors Market for Antibodies, 2023-2035
• Figure 9.11 Global Bioreactors Market for Vaccines, 2023-2035
• Figure 9.12 Global Bioreactors Market for Cell Therapies, 2023-2035
• Figure 9.13 Global Bioreactors Market for Other Biologics, 2023-2035
• Figure 9.14 Global Bioreactors Market, 2023-2035: Distribution by Key Geographical Regions
• Figure 9.15 Bioreactors Market in North America, 2023-2035
• Figure 9.16 Bioreactors Market in Europe, 2023-2035
• Figure 9.17 Bioreactors Market in Asia-Pacific, 2023-2035
• Figure 9.18 Bioreactors Market in Rest of the World, 2023-2035
• Figure 11.1 Concluding Remarks: Overall Market Landscape of Bioreactor Manufacturers
• Figure 11.2 Concluding Remarks: Geographical Distribution of Bioreactor Manufacturers
• Figure 11.3 Concluding Remarks: Capacity Analysis
• Figure 11.4 Concluding Remarks: Market Forecast

Bioreactors Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Fabrication Material (Glass, Stainless Steel and Single use), Type of Bioprocess (Batch, Fed-batch and Continuous), Type of Biologic (Antibodies, Vaccines, Cell Therapies and Other Biologics), and Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World)

The Bioreactors Market is valued at USD 16.7 billion in 2024 growing at a CAGR of 11.1% during the forecast period 2024-2035.

Bioreactors represent specialized vessels employed in upstream biomanufacturing to foster the growth of cells and tissues under precisely controlled conditions. These conditions encompass factors like temperature, pH, pressure, aeration, and nutrient levels, all aimed at optimizing the environment for live cells or cellular components. The primary goal is to facilitate the conversion of substrates into a diverse array of biological products. These products span from therapeutic proteins such as vaccines, fusion proteins, antibodies, hormones, interleukins, and enzymes to cutting-edge medicinal products like cell-based and oligonucleotide-based therapies, retroviral vectors for gene therapy, and sophisticated in vitro models mimicking 2D and 3D tissue constructs, essential for drug discovery research. Typically, these bioreactors, often cylindrical and made of stainless steel, vary in size from milliliters to several liters, tailored to different bioprocessing needs and operational modes.

The surge in global demand for biopharmaceutical products has significantly propelled the growth of the bioprocessing supplies market. As companies either establish their own biopharmaceutical manufacturing facilities or opt to outsource production to specialized organizations, the demand for clinical and commercial-scale bioreactors has skyrocketed. Current estimates, including both in-house and outsourced capacities, indicate a global bioreactors capacity exceeding 13 million liters. Given this immense demand, the bioreactors market has evolved into a competitive arena, featuring numerous active companies boasting expertise in designing, engineering, and manufacturing a wide spectrum of bioreactors tailored to diverse applications. Offerings range from traditional stainless-steel bioreactors to disposable/single-use bioreactors, stirred-tank bioreactors, small-scale bioreactors, air lift bioreactors, perfusion bioreactors, bubble column bioreactors, and photobioreactors.

Key Market Segments

Fabrication Material

Stainless Steel

Single Use

Glass

Type of Bioprocess

Batch and Fed-batch

Continuous

Type of Biologic

Antibodies

Vaccines

Cell Therapies

Other Biologics

Key Geographical Regions

North America

Europe

Asia-Pacific

Rest of the World

Research Coverage:

A comprehensive analysis of the overall market landscape of companies manufacturing bioreactors, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), region of headquarters, geographical reach (North America, Europe, Asia-Pacific and Rest of the World), capacity (micro-mini, small-scale, bench-scale, lab-scale, pilot-scale and large-scale), scale of operation (preclinical, clinical and commercial), scalability, type of bioprocess (batch, fed-batch and continuous), type of cell culture (2D cell culture, 3D cell culture and 4D cell culture), mode of operation (manual, semi-automatic and automatic) and type of end user (academic institutes and research laboratories, biopharmaceutical and pharmaceutical industries, contract manufacturing organizations, and contract research organizations).

Comprehensives company competitiveness analysis of bioreactor manufacturers based on manufacturer strength (in terms of years of experience and company size), portfolio strength (considering geographical reach, number of products in portfolio, type of bioreactor, capacity, scale of operation, scalability, type of bioprocess, type of cell culture, mode of operation and end users).

Comprehensive company profiles of leading players manufacturing bioreactors (shortlisted on the basis of cumulative strength of manufacturers and product portfolio); each profile includes a brief overview of the company, along with information on its financial information (if available), product portfolio, recent developments and an informed future outlook.

A projection of the global installed capacity of bioreactors for biologics, compiled from data sourced from various publicly available industry outlets. This estimation also includes a breakdown of the available capacity categorized by fabrication material (glass, stainless steel, and single-use), cell culture source (mammalian, microbial, and others), reactor volume (less than 2,000 L, 2,000 to 5,000 L, 5,001 to 10,000 L, and over 10,000 L), manufacturer type (in-house, hybrid, and Contract Manufacturing Organizations [CMOs]), and major geographical regions (North America, Europe, Asia-Pacific, and Rest of the World).

A case study on the market landscape of bioprocess controllers and automation systems, providing information on scale of operation (laboratory, clinical, and commercial), key features (scalability / ease to use, visual data display, remote accessibility, built-in system control sensors, expansive I/O compatibility and provisions for alarms / alerts), compatibility with bioreactor system (stirred tank (glass), single use bioreactor, stirred tank (steel), rocking motion), type of bioprocess (batch, fed-batch and perfusion), and type of process controlled (cell cultivation and microbial fermentation). In addition, the chapter presents details of companies involved in the development of bioprocess control software, upstream and downstream controllers, including information on their year of establishment, company size, and location of headquarters.

A comprehensive market forecast analysis has been conducted to assess the current market size and future prospects for the bioreactors market over the coming 11 years. Utilizing multiple parameters and anticipated adoption trends, coupled with primary validations, we have developed informed estimates for market size within the forecast period spanning from 2024 to 2035. This chapter presents detailed projections of both current and future opportunities within the market, segmented across various factors including fabrication material (glass, stainless steel, and single-use), bioprocess type (batch, fed-batch, and continuous), types of biologics (such as antibodies, vaccines, cell therapies, and other biologics), and key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World).

Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.

Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.

The report provides stakeholders with a pulse on the Bioreactors Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

Applikon Biotechnology

Bionet

Cytiva

Eppendorf

Merck

Ollital Technology

Parr Instrument Company

Sartorius

Shanghai Bailun Biological Technology

Solaris Biotech

Solida Biotech

Zhengzhou Laboao Instrument Equipment (LABAO)

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Key Market Insights
• 1.3. Scope of the Report
• 1.4. Research Methodology
• 1.5. Frequently Asked Questions
• 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Chapter Overview
• 3.2. Overview of Bioreactors
• 3.3. Components of a Bioreactor
• 3.4. Types of Bioreactors
  • 3.4.1. Classification based on Type of Bioprocess
  • 3.4.2. Classification based on Mode of Action
• 3.5. Applications of Bioreactors
• 3.6. Future Perspectives

4. BIOREACTOR MANUFACTURERS: MARKET LANDSCAPE

• 4.1. Chapter Overview
• 4.2. Bioreactor Manufacturers: Overall Market Landscape
  • 4.2.1. Analysis by Year of Establishment
  • 4.2.2. Analysis by Company Size
  • 4.2.3. Analysis by Region of Headquarters
  • 4.2.4. Analysis by Location of Headquarters
  • 4.2.5. Analysis by Year of Establishment and Region of Headquarters
  • 4.2.6. Analysis by Company Size and Region of Headquarters
  • 4.2.7. Analysis by Year of Establishment, Company Size and Region of Headquarters
  • 4.2.8. Analysis by Geographical Reach
  • 4.2.9. Analysis by Region of Headquarters and Geographical Reach
  • 4.2.10. Analysis by Capacity
  • 4.2.11. Analysis by Scale of Operation
  • 4.2.12. Analysis by Scalability
  • 4.2.13. Analysis by Type of Bioprocess
  • 4.2.14. Analysis by Type of Cell Culture
  • 4.2.15. Analysis by Mode of Operation
  • 4.2.16. Analysis by Type of End-user

5. COMPANY COMPETITIVENESS ANALYSIS

• 5.1. Chapter Overview
• 5.2. Assumptions / Key Parameters
• 5.3. Methodology
• 5.4. Company Competitiveness Analysis: Small Companies
  • 5.4.1. Company Competitiveness Analysis: Small Companies based in North America
  • 5.4.2. Company Competitiveness Analysis: Small Companies based in Europe
  • 5.4.3. Company Competitiveness Analysis: Small Companies based in Asia-Pacific and Rest of the World
• 5.5. Company Competitiveness Analysis: Mid-sized Companies
  • 5.5.1. Company Competitiveness Analysis: Mid-sized Companies based in North America
  • 5.5.2. Company Competitiveness Analysis: Mid-sized Companies based in Europe
  • 5.5.3. Company Competitiveness Analysis: Mid-sized Companies based in Asia-Pacific and Rest of the World
• 5.6. Company Competitiveness Analysis: Large and Very Large Companies

6. COMPANY PROFILES

• 6.1. Chapter Overview
• 6.2. Applikon Biotechnology (acquired by Getinge)
  • 6.2.1. Company Overview
  • 6.2.2. Product Portfolio
  • 6.2.3. Recent Developments and Future Outlook
• 6.3. Bionet
  • 6.3.1. Company Overview
  • 6.3.2. Product Portfolio
  • 6.3.3. Recent Developments and Future Outlook
• 6.4. Cytiva
  • 6.4.1. Company Overview
  • 6.4.2. Financial Information
  • 6.4.3. Product Portfolio
  • 6.4.4. Recent Developments and Future Outlook
• 6.5. Eppendorf
  • 6.5.1. Company Overview
  • 6.5.2. Financial Information
  • 6.5.3. Product Portfolio
  • 6.5.4. Recent Developments and Future Outlook
• 6.6. Merck
  • 6.6.1. Company Overview
  • 6.6.2. Financial Information
  • 6.6.3. Product Portfolio
  • 6.6.4. Recent Developments and Future Outlook
• 6.7. Ollital Technology
  • 6.7.1. Company Overview
  • 6.7.2. Product Portfolio
  • 6.7.3. Recent Developments and Future Outlook
• 6.8. Parr Instrument Company
  • 6.8.1. Company Overview
  • 6.8.2. Product Portfolio
  • 6.8.3. Recent Developments and Future Outlook
• 6.9. Sartorius
  • 6.9.1. Company Overview
  • 6.9.2. Financial Information
  • 6.9.3. Product Portfolio
  • 6.9.4. Recent Developments and Future Outlook
• 6.10. Shanghai Bailun Biological Technology
  • 6.10.1. Company Overview
  • 6.10.2. Product Portfolio
  • 6.10.3. Recent Developments and Future Outlook
• 6.11. Solaris Biotech (acquired by Donaldson Company)
  • 6.11.1. Company Overview
  • 6.11.2. Product Portfolio
  • 6.11.3. Recent Developments and Future Outlook
• 6.12. Solida Biotech
  • 6.12.1. Company Overview
  • 6.12.2. Product Portfolio
  • 6.12.3. Recent Developments and Future Outlook
• 6.13. Zhengzhou Laboao Instrument Equipment (LABAO)
  • 6.13.1. Company Overview
  • 6.13.2. Product Portfolio
  • 6.13.3. Recent Developments and Future Outlook

7. CAPACITY ANALYSIS

• 7.1. Chapter Overview
• 7.2. Key Assumptions and Methodology
  • 7.2.1 Bioreactors s: Global Installed Capacity of Biologics
    • 7.2.1.1. Analysis by Fabrication Material
    • 7.2.1.2. Analysis by Source of Cell Culture
    • 7.2.1.3. Analysis by Reactor Volume
    • 7.2.1.4. Analysis by Type of Manufacturer
    • 7.2.1.5. Analysis by Key Geographical Regions
• 7.3. Concluding Remarks

8. CASE STUDY: BIOPROCESS CONTROLLERS AND AUTOMATION SYSTEMS

• 8.1. Chapter Overview
• 8.2. Bioprocess Control Software: Overall Market Landscape
  • 8.2.1. Analysis by Scale of Operation
  • 8.2.2. Analysis by Key Features
  • 8.2.3. Analysis by Compatibility with System
  • 8.2.4. Analysis by Type of Process Controlled
• 8.3. Bioprocess Control Software Developers: Overall Market Landscape
  • 8.3.1. Analysis by Year of Establishment
  • 8.3.2. Analysis by Company Size
  • 8.3.3. Analysis by Location of Headquarters
• 8.4. Upstream Controllers: Overall Market Landscape
  • 8.4.1. Analysis by Scale of Operation
  • 8.4.2. Analysis by Key Features
  • 8.4.3. Analysis by Compatibility with Bioreactor System
  • 8.4.4. Analysis by Type of Bioprocess
  • 8.4.5. Analysis by Type of Process Controlled
• 8.5. Upstream Controller Developers: Overall Market Landscape
  • 8.5.1. Analysis by Year of Establishment
  • 8.5.2. Analysis by Company Size
  • 8.5.3. Analysis by Location of Headquarters
• 8.6. Downstream Controller Systems: Overall Market Landscape
  • 8.6.1. Analysis by Scale of Operation
  • 8.6.2. Analysis by Key Features
  • 8.6.3. Analysis by Type of System
  • 8.6.4. Analysis by Type of Bioprocess
  • 8.6.5. Analysis by Application Area
• 8.7. Downstream Controller System Developers: Overall Market Landscape
  • 8.7.1. Analysis by Year of Establishment
  • 8.7.2. Analysis by Company Size
  • 8.7.3. Analysis by Location of Headquarters

9. MARKET FORECAST

• 9.1. Chapter Overview
• 9.2. Key Assumptions and Forecast Methodology
• 9.3. Global Bioreactors Market, 2023-2035: Distribution by Fabrication Material
• 9.3. 1. Global Glass Bioreactors Market, 2023-2035
• 9.3. 2. Global Stainless Steel Bioreactors Market, 2023-2035
• 9.3. 3. Global Single use Bioreactors Market, 2023-2035
• 9.4. Global Bioreactors Market, 2023-2035: Distribution by Type of Bioprocess
  • 9.3.3.1. Global Bioreactors Market for Batch and Fed-batch Process, 2023-2035
  • 9.3.3.2. Global Bioreactors Market for Continuous Process, 2023-2035
  • 9.3.4. Global Bioreactors Market, 2023-2035: Distribution by Type of Biologic
    • 9.3.4.1. Global Bioreactors Market for Antibodies, 2023-2035
    • 9.3.4.2. Global Bioreactors Market for Vaccines, 2023-2035
    • 9.3.4.3. Global Bioreactors Market for Cell Therapies, 2023-2035
    • 9.3.4.4. Global Bioreactors Market for Other Biologics, 2023-2035
  • 9.3.5. Global Bioreactors Market, 2023-2035: Distribution by Key Geographical Regions
    • 9.3.5.1. Global Bioreactors Market in North America, 2023-2035
    • 9.3.5.2. Global Bioreactors Market in Europe, 2023-2035
    • 9.3.5.3. Global Bioreactors Market in Asia-Pacific, 2023-2035
    • 9.3.5.4. Global Bioreactors Market in Rest of the World, 2023-2035

10. EXECUTIVE INSIGHTS

11. CONCLUDING REMARKS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS